Nov. 17, 2015, 3:13 PM
- Thinly traded nano cap Cesca Therapeutics (KOOL -50.7%) craters on more than an 11x surge in volume in response to its announcement after the close yesterday that a big chunk of the money ($9.5M) it raised in its convertible debt offering won't be immediately available to fund its planned Phase 3 study of SurgWerks in critical limb ischemia (CLI).
- The money resides in a restricted control account and won't be released until certain milestones are met, including approval from the California Institute for Regenerative Medicine (CIRM) of the company's application for matching funds in the form of a CIRM grant. A decision by CIRM was expected later this month, but preliminary feedback indicated that the application would be rejected so Cesca withdrew its application. This puts the company in a serious financial bind since the Phase 3 study is projected to cost over $20M.
- Predictably, the company is quickly editing its application, specifically making changes to the anticipated rate of patient enrollment, the overall timetable and the design of the statistical plan, so it can resubmit it to CIRM. It will also accelerate its search for funding via strategic partnerships and/or license agreements.
Jan. 2, 2015, 9:14 AM
Nov. 20, 2014, 3:50 PM
- Thinly-traded nano cap Cesca Therapeutics (KOOL +16%) enjoys an up day on a 6x surge in volume albeit on turnover of ~380K shares.
- This morning the company announced its IDE filing for a Phase 3 multicenter study to evaluate the safety and efficacy of is SurgWerks-CLI and VXP System for the treatment of advanced stages of no-option lower limb critical limb ischemia. The primary endpoint of the proposed trial will be major amputation-free survival at 12 months.
Jun. 13, 2014, 12:46 PM
Jun. 10, 2014, 9:13 AM
May 1, 2014, 9:13 AM
Apr. 24, 2014, 12:46 PM
Apr. 24, 2014, 11:58 AM
- Nano cap Cesca Therapeutics (KOOL +26.2%) shows bullish price action with today's up move on a 10x surge in volume. It represents a successful retest of the January 21 breakout when prices popped 111% on massive turnover of 32.9M shares after the company announced positive Phase 1b clinical trial results for its stem cell therapy for critical limb ischemia.
- The company acquired development partner TotipotentRX shortly thereafter and changed its name from Thermogenesis.
- Last month, it submitted a pre-IDE information package to the FDA for the product, now called SurgWerks, as the first step in its commercialization efforts in the U.S.
- Considering its microscopic market cap of $66M, retail investors should insist on thorough due diligence before considering deploying capital.
- Corporate presentation
Apr. 24, 2014, 9:28 AM
Feb. 3, 2014, 12:51 PM
Jan. 28, 2014, 12:45 PM
Jan. 27, 2014, 9:27 AM
- ThermoGenesis (KOOL) has raised $6.67M in a private placement of stocks and warrants with institutional investors.
- ThermoGenesis is selling 3.33M shares at $2 each vs the company's close of $2.82 on Friday. The buyers will also receive warrants to purchase up to 1.66M shares at $2.81 each.
- The financing comes after ThermoGenesis last week announced positive results from a Phase Ib trial of stem-cell therapy to treat critical limb ischemia.
- Shares are -15.6% to $2.38 premarket. (PR)
Jan. 27, 2014, 9:09 AM
Jan. 22, 2014, 12:47 PM
Jan. 22, 2014, 9:09 AM
Jan. 21, 2014, 9:34 AM
- ThermoGenesis (KOOL) surges 32% after the company reported, along with its partner TotipotentRX, statistically significant results in five key areas in a Phase Ib trial of the latter's CLIRST stem-cell therapy for treating critical limb ischemia.
- The study comprised 17 patients and achieved its primary safety and secondary efficacy endpoints at 12 months.
- The areas that were assessed included survival rates that didn't require major amputations, a fall in resting and walking pain, improved walking distance and open wound healing.
- Critical limb ischemia is a severe blockage in the arteries in the lower extremities. (PR)
Cesca Therapeutics, Inc. engages in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It offers a therapeutic technology platform, SurgWerks, an intraoperative rapid system for harvesting, selection, testing, and delivering a... More
Industry: Medical Appliances & Equipment
Country: United States
Other News & PR